Prescription Drugs

Asahi Kasei Pharma discovers, develops, manufactures, and delivers prescription drugs in the fields of orthopedics, emergency and intensive care, the immune system, urology, and the central nervous system.

The product information contained in this website is intended for general information purposes. The names, descriptions, and labeling of approved products are of Japan origin. Product availability, names, indications, and presentations may vary from country to country.

Teribone™ is a human parathyroid hormone preparation that facilitates bone formation, for the indication of osteoporosis with weekly or twice weekly subcutaneous injections.

Reclast™ is a bisphosphonate agent that suppresses bone resorption, for the treatment of osteoporosis with once-a-year intravenous infusion.
Reclast™ is a registered trademark of Novartis.

Elcitonin™ Injection 20S is an osteoporosis therapeutic agent (calcitonin preparation) indicated for the treatment of pain associated with osteoporosis.

Recomodulin™ is a thrombomodulin agent produced through genetic engineering, indicated for the treatment of disseminated intravascular coagulation (DIC) associated with malignant tumors, infectious diseases, etc.

Cresemba™ is an azole antifungal drug for fungal infections, such as Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma), Mucormycosis, and Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis (including cryptococcal meningitis))

Doptelet® is a thrombopoietin receptor agonist, which is an agent for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure.
Asahi Kasei Pharma obtained exclusive distribution rights in Japan for Doptelet® for thrombocytopenia associated with chronic liver disease from Swedish Orphan Biovitrum Japan Co., Ltd.

Empaveli® is a PEGylated peptide1 inhibiting the function of complement protein C3 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Asahi Kasei Pharma obtained exclusive distribution rights in Japan for Empaveli® for PNH from Swedish Orphan Biovitrum Japan Co., Ltd.

Kevzara® is a human monoclonal antibody that blocks the action of IL-6, for the treatment of rheumatoid arthritis. Kevzara® is a registered trademark of Sanofi Biotechnology.

Plaquenil® is an immunomodulator indicated for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).
Plaquenil® is a registered trademark of Sanofi-Aventis U.S.

Bredinin™ is an immunosuppressant used in suppression of immune response following renal transplantation, and to treat nephrotic syndrome, lupus nephritis, and rheumatoid arthritis.

Flivas™ is an α1 blocker indicated for the treatment of dysuria (difficulty in urination, nocturia, and incomplete emptying, etc.) accompanying benign prostatic hyperplasia.

Toledomin™ is a type of antidepressant called SNRI (serotonin-norepinephrine reuptake inhibitor).
Toledomin™ is a registered trademark of Pierre Fabre Medicament SA.

Eril™ is a Rho-kinase inhibitor used to treat cerebral vasospasm and delayed cerebral ischemic symptoms after subarachnoid hemorrhage.

Famvir™ is an anti-herpes virus agent indicated for the treatment of herpes zoster and herpes simplex.
Famvir™ is marketed in Japan by Maruho Co., Ltd.
Famvir™ is a registered trademark of Novartis Pharma AG.